Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/8/2025 | $40.00 | Buy | H.C. Wainwright |
| 4/2/2025 | $18.00 | Buy | BTIG Research |
Dura Medical, together with pending acquisitions of Neurospa TMS and Cohen & Associates, to provide contiguous coverage at more than 8 locations along Florida's West Coast, with planned coverage throughout the Florida PeninsulaDura delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to Veterans and civilian patients Stephen Durand, CRNA, a US Army Veteran and founder of Dura will serve as Director of Clinic Operations for HOPE Therapeutics in Florida MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholl
WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D., M.P.H., Chairman and Chief Executive Officer of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 PM ET. A webcast of the fireside chat will be available on the Events page of the Investors section of the Company's webs
NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL during symposium presentation with leadership from Rockefeller Capital and Matthew Rockefeller.Company has recently raised $8.8 million capital from experienced biotech investors with no warrants, repricing, or other variable rate features.HOPE clinics will combine treatment with neuroplastic drugs including ketamine, transcranial magnetic stimulation, and hyperbaric oxygen to treat suicidal depression, PTSD, traumatic brain injury and other forms of cognitive dysfunction.Matthew Rockefeller is announced as joining the HOPE Therapeutics Advisory Board. SOUTHAMPTON
3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
424B5 - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $40.00
BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00
WILMINGTON, Del., July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat at BTIG Virtual Biotechnology Conference on July 29 – 30, 2025. Prof. Jonathan Javitt, MD, MPH will join Prof. Samuel Wilkinson, MD, of the Yale School of Medicine, and BTIG Research Analyst Dr. Thomas Shrader for a fireside chat to discuss neuroplasticity in the treatment of CNS disorders at 8:00 a.m. EDT on Wednesday, July 30, 2025. Prof. Wilkinson is a widely published psychiat
Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwideKadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this spaceDr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPEMIAMI, May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinic
WILMINGTON, Del., Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr. Michael Taylor and Ms. Anita Nunes as Member and Observer of its Board of Directors, respectively. Ms. Nunes is also to be appointed to the Board of Directors of Hope Therapeutics, Inc. Michael Taylor brings over 25 years of experience in global cr
NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need.Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a specific finding that NRX-100 addresses an "unmet medical need." This is a specific qualifying requirement for the Commissioner's National Priority Voucher Program.Filing of Commissioner's National Priority Voucher application for intravenous ketamine (NRX-100).Subm
Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call the following morning at 8:00am ET, Wednesday August 20, 2025. The Company requires addi
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day. The call will provide a corporate and financial update, with a focus on recent regulatory events, regulatory strategy and go forward operational plans. A live webcast of the conference call will be available on the Co
SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)
SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)
SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)